Vireo Growth (VREOF) Current Deferred Revenue (2020 - 2026)
Vireo Growth (VREOF) reported Current Deferred Revenue of $4.3 million for Q1 2026, up 260.28% on a YoY basis from $1.2 million in Q1 2025, and down 8.51% sequentially from $4.7 million in Q4 2025.
Vireo Growth (VREOF) Current Deferred Revenue (2020 - 2026) Analysis & Trends
Vireo Growth (VREOF) has 7 years of Current Deferred Revenue data on file, last reported at $4.3 million in Q1 2026.
- For the quarter ending Q1 2026, Current Deferred Revenue rose 260.28% year-over-year to $4.3 million; the trailing twelve-month figure through Mar 2026 stood at $4.3 million (up 260.28% YoY), and the FY2025 full-year result was $4.7 million, up 346.07% from the prior year.
- Current Deferred Revenue eased to $4.3 million in Q1 2026, from $4.7 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $4.7 million in Q4 2025 to a low of $450334.0 in Q1 2022.
- A 5-year average of $1.4 million and a median of $833832.0 in 2023 frame the typical range for Current Deferred Revenue.
- Across the five-year window, Current Deferred Revenue increased 13.22% in 2023 and surged 346.07% in 2025, its largest moves.
- Tracing VREOF's Current Deferred Revenue over 5 years: stood at $684703.0 in 2022, then gained by 21.78% to $833832.0 in 2023, then advanced by 26.36% to $1.1 million in 2024, then surged by 346.07% to $4.7 million in 2025, then fell by 8.51% to $4.3 million in 2026.
- Business Quant data shows VREOF's Current Deferred Revenue at $4.3 million in Q1 2026, $4.7 million in Q4 2025, and $2.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.30 Mn |
| Dec 31, 2025 | 4.70 Mn |
| Sep 30, 2025 | 2.46 Mn |
| Jun 30, 2025 | 2.43 Mn |
| Mar 31, 2025 | 1.19 Mn |
| Dec 31, 2024 | 1.05 Mn |
| Sep 30, 2024 | 921,785.00 |
| Jun 30, 2024 | 821,761.00 |
| Mar 31, 2024 | 885,696.00 |
| Dec 31, 2023 | 833,832.00 |
| Sep 30, 2023 | 732,775.00 |
| Jun 30, 2023 | 626,689.00 |
| Mar 31, 2023 | 710,117.00 |
| Dec 31, 2022 | 684,703.00 |
| Sep 30, 2022 | 647,208.00 |
| Jun 30, 2022 | 522,926.00 |
| Mar 31, 2022 | 450,334.00 |
| Dec 31, 2021 | 409,627.00 |
| Sep 30, 2021 | 424,448.00 |
| Jun 30, 2021 | 374,498.00 |